{"hands_on_practices": [{"introduction": "Before a radiomic feature can be used in a clinical trial, we must ensure it is reproducible. This practice introduces the Intraclass Correlation Coefficient (ICC), a key metric for quantifying test-retest reliability. By working through this problem, you will learn to calculate the ICC from its fundamental components—the variability between subjects and the variability from measurement error—to assess a feature's stability. [@problem_id:4557132]", "problem": "A prospective clinical trial in radiomics is designed to evaluate the test-retest reliability of a standardized texture feature extracted from Computed Tomography (CT) scans. At baseline, each enrolled subject undergoes two independent acquisitions on the same scanner using identical protocols. Let the feature value for subject $i$ on acquisition $j$ be represented by the one-way random effects model $Y_{ij} = \\mu + b_{i} + \\epsilon_{ij}$, where $i$ indexes subjects, $j \\in \\{1,2\\}$ indexes repeated measurements, $b_{i}$ is a subject-specific random effect with variance $\\sigma_{b}^{2}$, and $\\epsilon_{ij}$ is a measurement error term with variance $\\sigma_{w}^{2}$. Assume $b_{i}$ and $\\epsilon_{ij}$ are independent across indices and mutually independent. The Intraclass Correlation Coefficient (ICC) is defined as the correlation between two randomly selected measurements from the same subject under this model.\n\nIn a pilot run that mirrors the trial protocol, the variance components are estimated as $\\sigma_{b}^{2} = 0.36$ and $\\sigma_{w}^{2} = 0.24$. Using the model and these variance components, compute the ICC. Express your answer as a decimal with no units and round your answer to four significant figures.", "solution": "The user has provided a problem statement that has been validated and found to be well-posed, scientifically grounded, and consistent. The solution will proceed by deriving the formula for the Intraclass Correlation Coefficient (ICC) from first principles based on the provided one-way random effects model and then substituting the given variance components to compute its numerical value.\n\nThe problem defines the model for a feature value $Y_{ij}$ for subject $i$ on acquisition $j$ as:\n$$Y_{ij} = \\mu + b_{i} + \\epsilon_{ij}$$\nwhere $i$ indexes subjects, $j \\in \\{1,2\\}$ indexes the two repeated measurements, $\\mu$ is the overall mean feature value, $b_{i}$ is a subject-specific random effect, and $\\epsilon_{ij}$ is the random measurement error.\n\nThe following assumptions are given:\n1. The subject-specific effects $b_i$ are random variables with mean $0$ and variance $\\operatorname{Var}(b_i) = \\sigma_{b}^{2}$.\n2. The measurement errors $\\epsilon_{ij}$ are random variables with mean $0$ and variance $\\operatorname{Var}(\\epsilon_{ij}) = \\sigma_{w}^{2}$.\n3. The random variables $b_i$ and $\\epsilon_{ij}$ are mutually independent and independent across all indices.\n\nThe Intraclass Correlation Coefficient (ICC) is defined as the correlation between two measurements from the same subject. Let these two measurements be $Y_{i1}$ and $Y_{i2}$ for an arbitrary subject $i$. The formula for the correlation coefficient is:\n$$ \\text{ICC} = \\operatorname{Corr}(Y_{i1}, Y_{i2}) = \\frac{\\operatorname{Cov}(Y_{i1}, Y_{i2})}{\\sqrt{\\operatorname{Var}(Y_{i1}) \\operatorname{Var}(Y_{i2})}} $$\n\nFirst, we compute the total variance of a single measurement, $\\operatorname{Var}(Y_{ij})$. Since $\\mu$ is a constant, it does not contribute to the variance.\n$$ \\operatorname{Var}(Y_{ij}) = \\operatorname{Var}(\\mu + b_{i} + \\epsilon_{ij}) = \\operatorname{Var}(b_{i} + \\epsilon_{ij}) $$\nGiven that $b_i$ and $\\epsilon_{ij}$ are independent, the variance of their sum is the sum of their variances:\n$$ \\operatorname{Var}(Y_{ij}) = \\operatorname{Var}(b_i) + \\operatorname{Var}(\\epsilon_{ij}) = \\sigma_{b}^{2} + \\sigma_{w}^{2} $$\nThis total variance is the same for both measurements, so $\\operatorname{Var}(Y_{i1}) = \\operatorname{Var}(Y_{i2}) = \\sigma_{b}^{2} + \\sigma_{w}^{2}$.\n\nNext, we compute the covariance between the two measurements, $\\operatorname{Cov}(Y_{i1}, Y_{i2})$.\n$$ \\operatorname{Cov}(Y_{i1}, Y_{i2}) = \\operatorname{Cov}(\\mu + b_{i} + \\epsilon_{i1}, \\mu + b_{i} + \\epsilon_{i2}) $$\nUsing the properties of covariance:\n$$ \\operatorname{Cov}(Y_{i1}, Y_{i2}) = \\operatorname{Cov}(b_{i} + \\epsilon_{i1}, b_{i} + \\epsilon_{i2}) $$\n$$ \\operatorname{Cov}(Y_{i1}, Y_{i2}) = \\operatorname{Cov}(b_i, b_i) + \\operatorname{Cov}(b_i, \\epsilon_{i2}) + \\operatorname{Cov}(\\epsilon_{i1}, b_i) + \\operatorname{Cov}(\\epsilon_{i1}, \\epsilon_{i2}) $$\nFrom the independence assumptions:\n- $b_i$ and $\\epsilon_{i2}$ are independent, so $\\operatorname{Cov}(b_i, \\epsilon_{i2}) = 0$.\n- $\\epsilon_{i1}$ and $b_i$ are independent, so $\\operatorname{Cov}(\\epsilon_{i1}, b_i) = 0$.\n- $\\epsilon_{i1}$ and $\\epsilon_{i2}$ are independent for $j=1 \\neq 2$, so $\\operatorname{Cov}(\\epsilon_{i1}, \\epsilon_{i2}) = 0$.\n- By definition, $\\operatorname{Cov}(b_i, b_i) = \\operatorname{Var}(b_i) = \\sigma_{b}^{2}$.\n\nSubstituting these results, the covariance simplifies to:\n$$ \\operatorname{Cov}(Y_{i1}, Y_{i2}) = \\sigma_{b}^{2} $$\n\nNow, we can assemble the formula for the ICC:\n$$ \\text{ICC} = \\frac{\\sigma_{b}^{2}}{\\sqrt{(\\sigma_{b}^{2} + \\sigma_{w}^{2})(\\sigma_{b}^{2} + \\sigma_{w}^{2})}} = \\frac{\\sigma_{b}^{2}}{\\sigma_{b}^{2} + \\sigma_{w}^{2}} $$\nThis result shows that the ICC is the ratio of the between-subject variance ($\\sigma_{b}^{2}$) to the total variance ($\\sigma_{b}^{2} + \\sigma_{w}^{2}$).\n\nThe problem provides the estimated variance components from a pilot study:\n- Between-subject variance: $\\sigma_{b}^{2} = 0.36$\n- Within-subject variance (measurement error): $\\sigma_{w}^{2} = 0.24$\n\nSubstituting these values into the ICC formula:\n$$ \\text{ICC} = \\frac{0.36}{0.36 + 0.24} = \\frac{0.36}{0.60} $$\nPerforming the division:\n$$ \\text{ICC} = 0.6 $$\nThe problem requires the answer to be expressed as a decimal with four significant figures. Therefore, we write $0.6$ as $0.6000$.", "answer": "$$\\boxed{0.6000}$$", "id": "4557132"}, {"introduction": "A model's performance is not absolute; it is highly dependent on the clinical context in which it is used. This exercise demonstrates how a model's Negative Predictive Value (NPV), a critical measure of its utility, changes with the prevalence of the disease in the target population. By calculating the shift in NPV between two hypothetical clinical settings, you will gain a crucial understanding of why trial design and patient selection are paramount for validating a radiomic classifier. [@problem_id:4556988]", "problem": "A prospective, multi-center radiomics trial is being designed to evaluate a binary classifier that flags patients as test-positive ($T+$) or test-negative ($T-$) for a target condition ($D+$ for disease present, $D-$ for disease absent). The classifier will be deployed in two recruitment settings that differ in baseline disease prevalence. Pilot data suggest a sensitivity $\\mathrm{Se}=P(T+|D+)=0.80$ and a specificity $\\mathrm{Sp}=P(T-|D-)=0.95$. Setting A has disease prevalence $\\pi=P(D+)=0.30$ and Setting B has disease prevalence $\\pi=P(D+)=0.10$. The primary endpoint for trial feasibility is the Negative Predictive Value (NPV), defined as $P(D-|T-)$.\n\nStarting from the core definitions of conditional probability and Bayes’ theorem, and without assuming any specialized shortcut formulas, derive the expression for the Negative Predictive Value in terms of sensitivity $\\mathrm{Se}$, specificity $\\mathrm{Sp}$, and prevalence $\\pi$. Then, compute the absolute change in $\\mathrm{NPV}$ when moving from Setting A to Setting B (i.e., $\\mathrm{NPV}$ at $\\pi=0.10$ minus $\\mathrm{NPV}$ at $\\pi=0.30$), using the given $\\mathrm{Se}$ and $\\mathrm{Sp}$ values. Express your final answer as a decimal and round to four significant figures.", "solution": "The problem is assessed to be valid as it is scientifically grounded in the principles of biostatistics, well-posed, objective, and internally consistent.\n\nThe objective is to first derive the formula for the Negative Predictive Value (NPV) in terms of sensitivity ($\\mathrm{Se}$), specificity ($\\mathrm{Sp}$), and disease prevalence ($\\pi$), and then to compute the change in $\\mathrm{NPV}$ between two settings with different prevalences.\n\nThe Negative Predictive Value ($\\mathrm{NPV}$) is defined as the probability that a subject is disease-free ($D-$) given a negative test result ($T-$). Mathematically, this is expressed as the conditional probability:\n$$ \\mathrm{NPV} = P(D-|T-) $$\n\nThis can be solved using Bayes' theorem, which in this context is written as:\n$$ P(D-|T-) = \\frac{P(T-|D-) P(D-)}{P(T-)} $$\n\nWe will derive the components of this expression, the numerator $P(T-|D-) P(D-)$ and the denominator $P(T-)$, from the given parameters.\n\nThe givens are:\n-   Sensitivity: $\\mathrm{Se} = P(T+|D+) = 0.80$\n-   Specificity: $\\mathrm{Sp} = P(T-|D-) = 0.95$\n-   Prevalence: $\\pi = P(D+)$\n\nFirst, let's express the terms in the numerator, $P(T-|D-) P(D-)$, using the provided definitions.\nThe term $P(T-|D-)$ is the probability of a negative test given no disease, which is the definition of specificity, $\\mathrm{Sp}$.\nThe term $P(D-)$ is the probability of not having the disease. It is the complement of the prevalence, $\\pi$:\n$$ P(D-) = 1 - P(D+) = 1 - \\pi $$\nTherefore, the numerator is:\n$$ P(T-|D-) P(D-) = \\mathrm{Sp} (1 - \\pi) $$\n\nNext, we evaluate the denominator, $P(T-)$, which is the overall probability of receiving a negative test result. We can calculate this using the law of total probability by marginalizing over the disease status ($D+$ or $D-$):\n$$ P(T-) = P(T- \\cap D+) + P(T- \\cap D-) $$\nWe can expand each term using the definition of conditional probability, $P(A \\cap B) = P(A|B)P(B)$:\n$$ P(T- \\cap D+) = P(T-|D+) P(D+) $$\n$$ P(T- \\cap D-) = P(T-|D-) P(D-) $$\nSo, the denominator becomes:\n$$ P(T-) = P(T-|D+) P(D+) + P(T-|D-) P(D-) $$\nLet's substitute the given parameters into this expression.\nThe first term involves $P(T-|D+)$, which is the probability of a negative test given the disease is present. This is the False Negative Rate (FNR) and is the complement of sensitivity:\n$$ P(T-|D+) = 1 - P(T+|D+) = 1 - \\mathrm{Se} $$\nAnd $P(D+)$ is the prevalence, $\\pi$. So, the first term is $(1 - \\mathrm{Se})\\pi$.\nThe second term, $P(T-|D-) P(D-)$, is the same expression as the numerator we derived earlier: $\\mathrm{Sp}(1-\\pi)$.\nCombining these, the denominator is:\n$$ P(T-) = (1 - \\mathrm{Se})\\pi + \\mathrm{Sp}(1 - \\pi) $$\n\nNow, substituting the expressions for the numerator and denominator back into the Bayes' theorem formula for $\\mathrm{NPV}$, we get the general expression for $\\mathrm{NPV}$ in terms of $\\mathrm{Se}$, $\\mathrm{Sp}$, and $\\pi$:\n$$ \\mathrm{NPV} = \\frac{\\mathrm{Sp}(1-\\pi)}{(1 - \\mathrm{Se})\\pi + \\mathrm{Sp}(1 - \\pi)} $$\nThis completes the derivation part of the problem.\n\nNow, we compute the $\\mathrm{NPV}$ for Setting A and Setting B.\nThe given fixed parameters are $\\mathrm{Se} = 0.80$ and $\\mathrm{Sp} = 0.95$.\n\nFor Setting A, the prevalence is $\\pi_A = 0.30$.\n$$ \\mathrm{NPV}_A = \\frac{0.95(1 - 0.30)}{(1 - 0.80)(0.30) + 0.95(1 - 0.30)} $$\n$$ \\mathrm{NPV}_A = \\frac{0.95(0.70)}{(0.20)(0.30) + 0.95(0.70)} $$\n$$ \\mathrm{NPV}_A = \\frac{0.665}{0.06 + 0.665} $$\n$$ \\mathrm{NPV}_A = \\frac{0.665}{0.725} \\approx 0.917241379... $$\n\nFor Setting B, the prevalence is $\\pi_B = 0.10$.\n$$ \\mathrm{NPV}_B = \\frac{0.95(1 - 0.10)}{(1 - 0.80)(0.10) + 0.95(1 - 0.10)} $$\n$$ \\mathrm{NPV}_B = \\frac{0.95(0.90)}{(0.20)(0.10) + 0.95(0.90)} $$\n$$ \\mathrm{NPV}_B = \\frac{0.855}{0.02 + 0.855} $$\n$$ \\mathrm{NPV}_B = \\frac{0.855}{0.875} \\approx 0.977142857... $$\n\nThe problem asks for the absolute change in $\\mathrm{NPV}$ when moving from Setting A to Setting B, which is $\\Delta \\mathrm{NPV} = \\mathrm{NPV}_B - \\mathrm{NPV}_A$.\n$$ \\Delta \\mathrm{NPV} = 0.977142857... - 0.917241379... $$\n$$ \\Delta \\mathrm{NPV} = 0.059901478... $$\n\nFinally, we round the result to four significant figures. The first non-zero digit is $5$, so the first four significant figures are $5, 9, 9, 0$. The following digit is $1$, so we round down (truncate).\n$$ \\Delta \\mathrm{NPV} \\approx 0.05990 $$", "answer": "$$\\boxed{0.05990}$$", "id": "4556988"}, {"introduction": "Beyond simple accuracy, the true test of a radiomic model is its clinical utility: does using it lead to better outcomes? This practice introduces Decision Curve Analysis (DCA), a framework for evaluating whether a model-guided strategy does more good than harm. You will calculate the \"net benefit\" of a radiomics model by weighing the benefit of true positives against the cost of false positives, providing a quantitative answer to whether the model is truly useful in a clinical setting. [@problem_id:4557158]", "problem": "A radiomics-based risk model has been prospectively incorporated into the screening workflow of a planned clinical trial to triage whether each enrolled participant should undergo a confirmatory biopsy for a clinically actionable condition. In the trial protocol, the decision rule is to recommend biopsy if the model’s predicted probability exceeds a prespecified threshold probability $p_{t}=0.15$, which encodes the trade-off between the harm from unnecessary biopsies and the benefit of detecting actionable disease. To evaluate clinical utility using Decision Curve Analysis (DCA), net benefit is defined on the scale of true-positive equivalents per patient by combining the benefit of true positives and the harm of false positives at the chosen threshold probability.\n\nFrom first principles, derive the appropriate expression for net benefit at a threshold probability $p_{t}$, apply it to the radiomics-guided strategy at $p_{t}=0.15$, and compare it to the two baseline strategies: treating all ($\\text{treat-all}$), and treating none ($\\text{treat-none}$). A participant is classified as predicted positive if $p_{i} \\ge p_{t}$ and predicted negative otherwise. The dataset below presents the predicted probabilities $p_{i}$ from the radiomics model and the binary outcomes $Y_{i}$ (with $Y_{i}=1$ indicating that biopsy would reveal clinically actionable disease, and $Y_{i}=0$ otherwise) for $N=20$ consecutively enrolled participants:\n\n- Participant $1$: $p_{1}=0.02$, $Y_{1}=0$\n- Participant $2$: $p_{2}=0.10$, $Y_{2}=0$\n- Participant $3$: $p_{3}=0.18$, $Y_{3}=1$\n- Participant $4$: $p_{4}=0.23$, $Y_{4}=1$\n- Participant $5$: $p_{5}=0.85$, $Y_{5}=1$\n- Participant $6$: $p_{6}=0.40$, $Y_{6}=0$\n- Participant $7$: $p_{7}=0.12$, $Y_{7}=0$\n- Participant $8$: $p_{8}=0.33$, $Y_{8}=1$\n- Participant $9$: $p_{9}=0.55$, $Y_{9}=1$\n- Participant $10$: $p_{10}=0.07$, $Y_{10}=0$\n- Participant $11$: $p_{11}=0.65$, $Y_{11}=1$\n- Participant $12$: $p_{12}=0.27$, $Y_{12}=0$\n- Participant $13$: $p_{13}=0.90$, $Y_{13}=1$\n- Participant $14$: $p_{14}=0.16$, $Y_{14}=0$\n- Participant $15$: $p_{15}=0.14$, $Y_{15}=1$\n- Participant $16$: $p_{16}=0.03$, $Y_{16}=0$\n- Participant $17$: $p_{17}=0.72$, $Y_{17}=1$\n- Participant $18$: $p_{18}=0.20$, $Y_{18}=0$\n- Participant $19$: $p_{19}=0.47$, $Y_{19}=1$\n- Participant $20$: $p_{20}=0.11$, $Y_{20}=0$\n\nFor the purpose of reporting, provide only the radiomics-guided strategy’s net benefit at $p_{t}=0.15$. Express the final net benefit as a decimal number with no units. Round your answer to four significant figures.", "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It presents a standard application of Decision Curve Analysis (DCA) to evaluate a radiomics model in a clinical trial context. All necessary data and definitions are provided.\n\nThe primary task is to derive the expression for net benefit and apply it to the given dataset for a radiomics-guided strategy at a specified threshold probability $p_t$.\n\nFirst, we derive the formula for net benefit from first principles. Net benefit quantifies the clinical utility of a model by balancing the benefit of true positives (correctly identifying patients with the condition) against the harm of false positives (incorrectly identifying patients who do not have the condition).\n\nLet $p_t$ be the threshold probability at which a clinician or patient is willing to accept the intervention (e.g., biopsy). This threshold implies a specific trade-off. At this point of indifference, the expected benefit of intervention equals the expected benefit of non-intervention. For a patient with a probability of disease $p$, the expected value of intervening is $p \\times \\text{Benefit(TP)} - (1-p) \\times \\text{Harm(FP)}$. We assume the value of not intervening is zero. At the threshold $p_t$, the decision-maker is indifferent, so:\n$$p_t \\times \\text{Benefit(TP)} - (1-p_t) \\times \\text{Harm(FP)} = 0$$\nThis yields the relative harm of a false positive compared to the benefit of a true positive:\n$$\\frac{\\text{Harm(FP)}}{\\text{Benefit(TP)}} = \\frac{p_t}{1-p_t}$$\nThe total net benefit for a population is the sum of benefits accrued from true positives minus the sum of harms from false positives. Let $\\text{TP}$ be the count of true positives and $\\text{FP}$ be the count of false positives in a population of size $N$.\n$$\\text{Total Net Benefit} = \\text{TP} \\times \\text{Benefit(TP)} - \\text{FP} \\times \\text{Harm(FP)}$$\nTo standardize the measure, DCA defines the net benefit per patient and expresses it in units of true positives. This is achieved by dividing the total net benefit by $N$ and by the benefit of one true positive:\n$$\\text{Net Benefit} = \\frac{\\text{TP} \\times \\text{Benefit(TP)} - \\text{FP} \\times \\text{Harm(FP)}}{N \\times \\text{Benefit(TP)}} = \\frac{\\text{TP}}{N} - \\frac{\\text{FP}}{N} \\left( \\frac{\\text{Harm(FP)}}{\\text{Benefit(TP)}} \\right)$$\nSubstituting the trade-off ratio, we obtain the standard formula for net benefit at a given threshold $p_t$:\n$$\\text{Net Benefit}(p_t) = \\frac{\\text{TP}}{N} - \\frac{\\text{FP}}{N} \\left( \\frac{p_t}{1-p_t} \\right)$$\nThe problem provides a dataset of $N=20$ participants and specifies a decision threshold of $p_t = 0.15$. A participant is recommended for biopsy (predicted positive) if their model-predicted probability $p_i$ is greater than or equal to $p_t$. We must now classify each of the $20$ participants as a true positive (TP), false positive (FP), true negative (TN), or false negative (FN).\n\nThe decision rule is:\n- Predicted Positive if $p_i \\ge 0.15$.\n- Predicted Negative if $p_i < 0.15$.\n\nWe tabulate the classifications:\n1. $p_{1}=0.02 < 0.15$, $Y_{1}=0$ $\\implies$ TN\n2. $p_{2}=0.10 < 0.15$, $Y_{2}=0$ $\\implies$ TN\n3. $p_{3}=0.18 \\ge 0.15$, $Y_{3}=1$ $\\implies$ TP\n4. $p_{4}=0.23 \\ge 0.15$, $Y_{4}=1$ $\\implies$ TP\n5. $p_{5}=0.85 \\ge 0.15$, $Y_{5}=1$ $\\implies$ TP\n6. $p_{6}=0.40 \\ge 0.15$, $Y_{6}=0$ $\\implies$ FP\n7. $p_{7}=0.12 < 0.15$, $Y_{7}=0$ $\\implies$ TN\n8. $p_{8}=0.33 \\ge 0.15$, $Y_{8}=1$ $\\implies$ TP\n9. $p_{9}=0.55 \\ge 0.15$, $Y_{9}=1$ $\\implies$ TP\n10. $p_{10}=0.07 < 0.15$, $Y_{10}=0$ $\\implies$ TN\n11. $p_{11}=0.65 \\ge 0.15$, $Y_{11}=1$ $\\implies$ TP\n12. $p_{12}=0.27 \\ge 0.15$, $Y_{12}=0$ $\\implies$ FP\n13. $p_{13}=0.90 \\ge 0.15$, $Y_{13}=1$ $\\implies$ TP\n14. $p_{14}=0.16 \\ge 0.15$, $Y_{14}=0$ $\\implies$ FP\n15. $p_{15}=0.14 < 0.15$, $Y_{15}=1$ $\\implies$ FN\n16. $p_{16}=0.03 < 0.15$, $Y_{16}=0$ $\\implies$ TN\n17. $p_{17}=0.72 \\ge 0.15$, $Y_{17}=1$ $\\implies$ TP\n18. $p_{18}=0.20 \\ge 0.15$, $Y_{18}=0$ $\\implies$ FP\n19. $p_{19}=0.47 \\ge 0.15$, $Y_{19}=1$ $\\implies$ TP\n20. $p_{20}=0.11 < 0.15$, $Y_{20}=0$ $\\implies$ TN\n\nCounting the total number of true positives and false positives:\n- Number of True Positives ($TP$): $9$\n- Number of False Positives ($FP$): $4$\n\nNow we can calculate the net benefit for the radiomics-guided strategy using the derived formula with $N=20$ and $p_t=0.15$:\n$$\\text{Net Benefit}(0.15) = \\frac{TP}{N} - \\frac{FP}{N} \\left( \\frac{p_t}{1-p_t} \\right)$$\n$$\\text{Net Benefit}(0.15) = \\frac{9}{20} - \\frac{4}{20} \\left( \\frac{0.15}{1-0.15} \\right)$$\n$$\\text{Net Benefit}(0.15) = \\frac{9}{20} - \\frac{4}{20} \\left( \\frac{0.15}{0.85} \\right)$$\nThe weight term is $\\frac{0.15}{0.85} = \\frac{15}{85} = \\frac{3}{17}$.\n$$\\text{Net Benefit}(0.15) = \\frac{9}{20} - \\frac{4}{20} \\left( \\frac{3}{17} \\right)$$\n$$\\text{Net Benefit}(0.15) = \\frac{9}{20} - \\frac{12}{340}$$\nTo compute this, we can use a common denominator of $340$:\n$$\\frac{9}{20} = \\frac{9 \\times 17}{20 \\times 17} = \\frac{153}{340}$$\n$$\\text{Net Benefit}(0.15) = \\frac{153}{340} - \\frac{12}{340} = \\frac{153-12}{340} = \\frac{141}{340}$$\nNow, we compute the decimal value:\n$$\\frac{141}{340} \\approx 0.41470588...$$\nThe problem requires the answer to be rounded to four significant figures.\n$$\\text{Net Benefit}(0.15) \\approx 0.4147$$\nThis value can be compared to the net benefit of the baseline strategies. For \"treat-none\", the net benefit is always $0$. For \"treat-all\", the true positives are all patients with the condition ($10$ in this cohort) and false positives are all patients without the condition ($10$ in this cohort).\n$$\\text{Net Benefit}_{\\text{all}} = \\frac{10}{20} - \\frac{10}{20} \\left( \\frac{3}{17} \\right) = \\frac{1}{2} - \\frac{1}{2} \\left( \\frac{3}{17} \\right) = \\frac{1}{2} \\left( 1 - \\frac{3}{17} \\right) = \\frac{1}{2} \\left( \\frac{14}{17} \\right) = \\frac{7}{17} \\approx 0.4118$$\nSince $0.4147 > 0.4118 > 0$, the radiomics-guided strategy demonstrates the highest clinical utility at this threshold. The requested output is only the net benefit of the radiomics-guided strategy.", "answer": "$$\\boxed{0.4147}$$", "id": "4557158"}]}